ResearcherBoston UniversityNo recent work listed

Trevor J. Grant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0001-5478-1824; OpenAlex author ID A5090562672. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper

Papers 2

STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Co-author DOI 10.18632/oncotarget.20833 ↗
Molecular Pathogenesis of Pancreatic Cancer. Co-author DOI 10.1016/bs.pmbts.2016.09.008 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Anurag Singh · 2 shared papers, 2016–2017 · strength 0.16
- Paper Molecular Pathogenesis of Pancreatic Cancer. DOI 10.1016/bs.pmbts.2016.09.008 ↗
- Paper STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. DOI 10.18632/oncotarget.20833 ↗
David Tsai Ting · 1 shared paper, 2017 · strength 0.06
- Paper STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. DOI 10.18632/oncotarget.20833 ↗
Vikram Deshpande · 1 shared paper, 2017 · strength 0.06
- Paper STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. DOI 10.18632/oncotarget.20833 ↗
Nabeel M. Bardeesy · 1 shared paper, 2017 · strength 0.06
- Paper STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. DOI 10.18632/oncotarget.20833 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.